Navigation Links
New proteomics project to develop technology to detect liver disease via blood test
Date:4/18/2008

RICHLAND, Wash. -- No simple blood test exists to determine which of the millions of people infected with hepatitis C virus will develop cirrhosis of the liver or cancer. Now, researchers are developing new technology to find blood proteins that herald the earliest signs of chronic liver disease. If successful, they hope to extend the use of the technology, and to do the same for many other diseases and to make it commercially available for broad clinical use.

Washington State's Life Sciences Discovery Fund Board of Trustees announced today that the collaboration between scientists at the Department of Energy's Pacific Northwest National Laboratory and the University of Washington Liver Transplantation Program in Seattle will receive $4.8 million over the next three years to develop a new proteomics technology and apply it in search of biomarkers for liver disease.

"This is really fantastic," says grant recipient and lead investigator Dick Smith of PNNL. "This funding will support work that is almost impossible to get funded by conventional sources. The grant brings together a larger program that could have significant positive impacts on the health of people, certainly in Washington, but in the whole country as well."

The announcement caps a lengthy selection process by LSDF. This has been a highly-competitive process. The proposals were weighed on their scientific merits and their abilities to utilize this funding to provide statewide economic returns, to build a competitive life sciences industry and to advance the health of, and health care for, our citizens. These newly-awarded grants will leverage substantial additional investment in Washington State by a variety of other funders such as federal agencies and philanthropic organizations, says LSDF Executive Director Lee Huntsman.

About 1.6 percent of the U.S. population has signs indicating they have been or are infected with hepatitis C virus, and up to 12,000 people each year die from HCV-induced liver damage and cancer. A percentage of infected people develop various levels of liver disease -- the worst requiring liver transplants -- but doctors have no way of telling who's most at risk.

PNNL's Smith is leading development of the new technology at DOE's Environmental Molecular Sciences Laboratory on the PNNL campus. In collaboration with UW's Michael Katze, Smith's group with use proteomics to compare blood and tissue samples from individuals who have advanced liver disease or are healthy to find proteins that indicate the potential for advanced illness.

The researchers' long term goal is to make such technology efficient and inexpensive enough for use in clinical settings. In addition, Smith's development plans include making the technology widely applicable to biomarker searches for other diseases.


'/>"/>

Contact: Mary Beckman
mary.beckman@pnl.gov
509-375-3688
DOE/Pacific Northwest National Laboratory
Source:Eurekalert

Related medicine news :

1. Story ideas from Molecular and Cellular Proteomics
2. Story ideas from molecular & cellular proteomics
3. Lake Hospital System Selected as Pilot Site for Health Information Literacy Research Project
4. Commerzbank Goes Live With Misys Risk Vision 5.4, Following a Successful, On Schedule Implementation Project
5. WXYZ-TV Announces 29th Annual Project Healthy Living
6. HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project
7. Childrens Hospital of Pittsburgh of UPMC Involved in Projects To Develop Nations First Heart Assist Devices for Young Children
8. SNM congratulates NOPR and its supporting organizations on successful conclusion of project
9. Oscar-Nominated Filmmaker Alejandro Gonzalez Inarritu Directs New Meth Project Advertising Campaign
10. Breckenridge Pharmaceutical Enters Agreement With Helm AG (Hamburg, Germany) to Develop Additional ANDA Project
11. URAC Announces Support for Principles of Disclosure Projects Patient Charter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: